Skip to search formSkip to main contentSkip to account menu

S-18886

Known as: S18886 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

terutroban

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Histamine-dependent prolongation by aldosterone of vasoconstriction in isolated small mesenteric arteries of the mouse.
In arterioles, aldosterone counteracts the rapid dilatation (recovery) following depolarization-induced contraction. The… 
2008
2008
Thromboxane Receptor Activation Mediates Isoprostane-Induced Increases in Amyloid Pathology in Tg2576 Mice
Alzheimer's disease (AD) amyloid plaques are composed of amyloid-β (Aβ) peptides produced from proteolytic cleavage of amyloid… 
Highly Cited
2007
Highly Cited
2007
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis
Summary Acute thrombosis is a threat in patients undergoing percutaneous coronary intervention with stent implantation. Our… 
2007
2007
Renal Effects of S18886 (Terutroban), a TP Receptor Antagonist, in an Experimental Model of Type 2 Diabetes
Thromboxane A2 (TxA2) is assumed to contribute to the development of diabetes complications, including nephropathy. We… 
2006
2006
Preclinical Evaluation of S18886 in an Experimental Model of Coronary Arterial Thrombosis
The specific thromboxane receptor antagonist, S18886, was evaluated for prevention of coronary arterial thrombosis and myocardial… 
Highly Cited
2005
Highly Cited
2005
Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study.
AIMS Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in atherogenesis. A growing body of… 
Highly Cited
2005
Highly Cited
2005
The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies
Summary.  Objectives and patients: We conducted a multicenter double‐blind pharmacokinetic/pharmacodynamic (PK/PD) study of the… 
2005
2005
Antithrombotic Properties of the Thromboxane A2/Prostaglandin H2 Receptor Antagonist S18886 on Prevention of Platelet-Dependent Cyclic Flow Reductions in Dogs
A potent thromboxane A2/PGH2 (TP)-receptor antagonist, S18886, was evaluated for its antithrombotic property in a dog model of… 
Review
2002
Review
2002
S-18886 Servier.
S-18886, the active isomer of S-18204, is a thromboxane A2 receptor antagonist with a long duration of action. The compound is… 
2000
2000
The new thromboxane receptor antagonist, S18886, but not aspirin inhibits atherogenesis in apo E deficient mice
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)